characteristics.text: SAMN40216026
characteristics.characteristic: External Id
characteristics.text: pRED Pharmaceutical Sciences, F. Hoffmann - La Roche Ltd
characteristics.characteristic: INSDC center name
characteristics.text: 2024-03-03T00:00:00Z
characteristics.characteristic: INSDC first public
characteristics.text: 2024-03-03T14:36:05.747Z
characteristics.characteristic: INSDC last update
characteristics.text: SRS20632383
characteristics.characteristic: INSDC secondary accession
characteristics.text: live
characteristics.characteristic: INSDC status
characteristics.text: Generic
characteristics.characteristic: NCBI submission model
characteristics.text: Generic.1.0
characteristics.characteristic: NCBI submission package
characteristics.text: SRS20632383
characteristics.characteristic: SRA accession
characteristics.text: subcutaneous
characteristics.characteristic: cell injection_route
characteristics.text: OCI-Ly18
characteristics.characteristic: cell line
characteristics.text: Lymphoma
characteristics.characteristic: cell type
characteristics.text: missing
characteristics.characteristic: collection_date
characteristics.text: D21
characteristics.characteristic: experimental day
characteristics.text: missing
characteristics.characteristic: geo_loc_name
characteristics.text: humanized mice
characteristics.characteristic: mouse strain
characteristics.text: Homo sapiens
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_9606
characteristics.characteristic: organism
characteristics.text: Tumor
characteristics.characteristic: source_name
characteristics.text: Tumor
characteristics.characteristic: tissue
characteristics.text: OCI-Ly18 cells (s.c.), Gazyva + glofitamab + CD19-CD28 (D21), D10
characteristics.characteristic: title
characteristics.text: Gazyva + glofitamab + CD19-CD28
characteristics.characteristic: treatment